Mexico is undergoing one of the most significant regulatory transformations in its history—and for U.S. technology companies and medical device manufacturers, this represents an unprecedented opportunity to enter the Latin American market faster than ever before.
The Big Picture: A 30-Day Pathway to Market
In July 2025, Mexico’s health regulator COFEPRIS published a new Equivalency Agreement that fundamentally changes how medical products are approved in the country. The core principle is regulatory reliance—COFEPRIS will now recognize approvals from trusted international authorities, eliminating the need for duplicate testing and documentation.
For manufacturers with approvals from recognized regulators, the review period is capped at just 30 business days. This represents a massive reduction from the 1–3 years traditionally required.
Which Countries Are Recognized?
COFEPRIS now recognizes approvals from:
- IMDRF Management Committee members: United States (FDA), Canada, Japan, European Union, United Kingdom, Australia, Brazil, Singapore, South Korea, Switzerland, and China (NMPA)
- MDSAP participants: Countries participating in the Medical Device Single Audit Program
What This Means for U.S. Companies
1. FDA Approval Is Your Ticket In
If your device already has FDA approval, you’re already 70–80% of the way to Mexican market entry. The remaining requirements are primarily administrative:
- Spanish-language labeling (NOM-137 compliant)
- Certificate of Free Sale
- Good Manufacturing Practice (GMP) certification
- Translation of technical documentation
2. The “Identical Device” Rule
COFEPRIS requires that the device submitted for Mexican approval is identical to the one approved by the reference authority—same formulation, manufacturing process, intended use, and technical specifications.
3. No Need to Reinvent the Wheel
Manufacturers can “lean on the robustness of prior evaluations” rather than duplicating testing and documentation. This reduces the regulatory burden by an estimated 70–80%.
Additional Regulatory Modernization
COFEPRIS has also:
- Eliminated 86 physical document requirements and consolidated 44 application codes
- Reclassified 2,088 medical devices as no longer requiring health registration
- Aligned Mexican Pharmacopoeia standards with international frameworks, including new Software as a Medical Device (SaMD) guidelines
Why This Matters for AI Voice Technology
Mexico’s digital transformation agenda is explicitly supporting AI and technology adoption in healthcare. The Simplified Registration Agreement is part of a broader push to modernize the country’s regulatory framework and position Mexico as “Latin America’s leading medtech innovation hub”.
For AI voice companies, this means the regulatory environment is not only open—it’s actively encouraging innovation.
What This Means for Puente Partners
This regulatory shift creates a clear need for a partner who understands both the U.S. technology landscape and the Mexican regulatory environment. Companies need help navigating:
- The equivalency application process
- Spanish-language labeling requirements
- Local representation and relationship building
- Post-market surveillance (Techno vigilance) obligations
That’s where Puente Partners comes in.